3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
44
Recruiting
4
Withdrawn
3
Terminated
2
Active not recruiting
2
Unknown
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
19
Sarcoma
4
Gynecologic
4
Gastrointestinal
4
Thoracic
3
Genitourinary
3
Endocrine
3
Breast
3
NET
2
Dermatologic
2
CNS
2
Other solid neoplasm
1
Lymphoid
1
Conditions
Brain Neoplasms
151
Glioblastoma
147
Glioma
95
Neuroblastoma
50
Medulloblastoma
33
Central Nervous System Neoplasms
27
Astrocytoma
27
Neoplasms
24
Ependymoma
23
Sarcoma
22
Carcinoma, Non-Small-Cell Lung
22
Neurofibromatosis 1
21
Melanoma
20
Breast Neoplasms
20
Rhabdomyosarcoma
18
Osteosarcoma
18
Sarcoma, Ewing
16
Lung Neoplasms
16
Gliosarcoma
16
Rhabdoid Tumor
15
Oligodendroglioma
15
Diffuse Intrinsic Pontine Glioma
14
Wilms Tumor
13
Meningioma
13
Hepatoblastoma
13
Recurrence
12
Neurofibroma, Plexiform
11
Neoplasm Metastasis
11
Meningeal Carcinomatosis
11
Lymphoma, Non-Hodgkin
11
Interventions
entrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Salivary Gland Neoplasms
×
CNS
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA